Christensen James 4

What Happened James Christensen, a member of Boundless Bio’s (BOLD) board of directors, received a grant of a derivative award on June 15, 2026: a stock option covering 32,000 shares reported at an acquisition price of $0. This was an award/grant (transaction code A), not a purchase or sale, so no cash changed hands and no shares were sold.

Key Details

• Transaction date: 2026-06-15; transaction type: Award/Grant (derivative) of 32,000 shares @ $0.00 (reported).
• Filing date: 2026-06-15 (filed timely; no late filing indicated).
• Shares owned after transaction: Not reported in the supplied filing details.
• Footnote (vesting): The option vests in substantially equal monthly installments over the 12 months following June 15, 2026 — or, if the issuer’s next annual meeting occurs before June 15, 2027, any remaining unvested portion will vest on that meeting date — subject to Christensen’s continued service on the board.

Context This was a director compensation grant (common for non-employee directors) rather than a market buy or sale. It represents potential future equity if the option vests and is exercised; it does not indicate an immediate purchase or sale of stock. For retail investors, grants are informational about compensation practices but are not direct signals of insider buying or selling.